恆指午後升幅擴至逾500點 京東、藥明生物及招行漲逾6%-8%
國務院總理李克強促請多省政府盡量於本月推措施令經濟更快回復正軌;內地今天五年期貸款市場報價利率(LPR)下調15點子至4.45%超預期。此外,美國總統拜登可能於未來幾周與中國國家主席習近平通電話。美股期貨全面回升0.7%-1.2%,道指期貨彈力較弱,報31,404,回升202點。亞太股市普遍升逾1%-2%,印度及港股彈力最強,孟買指數現報54,050,回升2.4%,結束兩連跌。
恆指繼昨日二萬關及10天線失而復得後,今早最多反彈482點或2.4%高見20,602遇壓,曾回順至20,408拒絕再下,半日升1.8%,午後升破今早高位,報20,663,回升542點或2.7%,成交額812億元。
藍籌股普遍反彈,尤其是藥明生物(02269.HK)扭兩連跌,股價重越10天及20天線,午後升幅擴至逾8%,報56.5元。阿里健康(00241.HK)彈逾5%報4.41元。
金融股以招行(03968.HK)彈力最強,最高見49.2元,現報49.1元,回升7.3%。中國平安(02318.HK)及友邦(01299.HK)升逾2.5%-3%,分別報48.2元及80.2元,股價分別重越10天線(47.6元)及50天線(78.2元)。
下周一晚啟動「618」促銷活動的京東(09618.HK)重越10天線(206.8元),午後股價高見213.4元,現報212.8元,回升6.5%。
騰訊(00700.HK)、網易(09999.HK)、美團(03690.HK)及阿里巴巴(09988.HK)彈3.1%-5%,後者最強,報87.5元。手機股小米(01810.HK)、舜宇(02382.HK)及瑞聲(02018.HK)也漲半成。
然而,碧桂園服務(06098.HK)逆市反覆回吐2.4%報30.3元。美國昨晚多項經濟數據均遜預期,出口股創科(00669.HK)反覆續跌逾1%報97.3元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.